Survival outcomes after radiotherapy for synchronous oligometastatic prostate cancer

With improvement in imaging for prostate cancer, diagnosis of oligometastatic disease (≤ 5 metastatic sites) has substantially increased. A retrospective cohort study at the University of Nebraska Medical Center (Omaha, NE) assessed survival outcomes after stereotactic body radiotherapy to the prostate and metastatic sites, combined with androgen deprivation therapy, in patients with synchronous oligometastatic castration-sensitive prostate cancer. Overall, radiotherapy was well tolerated. At median follow-up of 4 years (range 2-12), 20% of patients with M1 disease and 15.2% of patients with N1-only disease experienced biochemical failure. All known failure locations were local. The mean (SE) Kaplan-Meier estimate for survival time was 10.60 (0,81) years. The authors conclude that these findings represent great potential for metastasis-directed therapy.